F Rainer1, A Horvath1,2,3, T D Sandahl4, B Leber2,3, B Schmerboeck2,3, A Blesl1, A Groselj-Strele5, R E Stauber1, P Fickert1, P Stiegler2, H J Møller4, H Grønbaek4, V Stadlbauer1. 1. Department of Gastroenterology and Hepatology, Medical University of Graz, Austria. 2. Department of Transplantation Surgery, Medical University of Graz, Austria. 3. Center for Biomarker Research in Medicine (CBmed), Graz, Austria. 4. Departments of Hepatology and Gastroenterology, and Clinical Biochemistry, Denmark. 5. Core Facility Computational Bioanalytics, Medical University of Graz, Austria.
Abstract
BACKGROUND: Activated hepatic macrophages play a key role in inflammation and fibrosis progression in chronic liver disease. AIM: To assess the prognostic value of soluble (s)CD163 and mannose receptor (sMR) in cirrhotic patients and explore associations with markers of intestinal permeability (lactulose-mannitol ratio, diamine oxidase), bacterial translocation (endotoxin, lipopolysaccharide-binding protein) and markers of systemic immune activation (interleukin-6, interleukin-8, sCD14). METHODS: We prospectively investigated 101 cirrhotic patients (Child-Pugh class A: n = 72, Child-Pugh classes B and C: n = 29) and 31 healthy controls. Patients were observed for a median follow-up of 37 months. RESULTS: Median plasma levels of sCD163 and soluble mannose receptor were significantly elevated in cirrhotic patients (P < .001) and increased with disease severity (sCD163 in healthy controls = 1.3, Child-Pugh class A = 4.2, Child-Pugh classes B and C = 8.4 mg/L; sMR in healthy controls = 15.8, Child-Pugh class A = 36.5, Child-Pugh classes B and C = 66.3 μg/dL). A total of 21 patients died during the observation period. Patients with sCD163 levels above 5.9 mg/L showed significantly reduced survival (survival rate after 36 months: 71% versus 98%, P < .001). Patients with soluble mannose receptor levels above 45.5 μg/dL developed significantly more complications of cirrhosis within 12 months (73% versus 9%, P < .001). Furthermore, both variables correlated with the lactulose-mannitol ratio, diamine oxidase, lipopolysaccharide and interleukin-8. CONCLUSION: Our data demonstrate the prognostic value of sCD163 in predicting long-term survival in patients with liver cirrhosis and identify soluble mannose receptor as a prognostic marker for occurrence of cirrhosis-associated complications. The correlation between gut barrier dysfunction and activation of macrophages points towards a link between them.
BACKGROUND: Activated hepatic macrophages play a key role in inflammation and fibrosis progression in chronic liver disease. AIM: To assess the prognostic value of soluble (s)CD163 and mannose receptor (sMR) in cirrhotic patients and explore associations with markers of intestinal permeability (lactulose-mannitol ratio, diamine oxidase), bacterial translocation (endotoxin, lipopolysaccharide-binding protein) and markers of systemic immune activation (interleukin-6, interleukin-8, sCD14). METHODS: We prospectively investigated 101 cirrhotic patients (Child-Pugh class A: n = 72, Child-Pugh classes B and C: n = 29) and 31 healthy controls. Patients were observed for a median follow-up of 37 months. RESULTS: Median plasma levels of sCD163 and soluble mannose receptor were significantly elevated in cirrhotic patients (P < .001) and increased with disease severity (sCD163 in healthy controls = 1.3, Child-Pugh class A = 4.2, Child-Pugh classes B and C = 8.4 mg/L; sMR in healthy controls = 15.8, Child-Pugh class A = 36.5, Child-Pugh classes B and C = 66.3 μg/dL). A total of 21 patients died during the observation period. Patients with sCD163 levels above 5.9 mg/L showed significantly reduced survival (survival rate after 36 months: 71% versus 98%, P < .001). Patients with soluble mannose receptor levels above 45.5 μg/dL developed significantly more complications of cirrhosis within 12 months (73% versus 9%, P < .001). Furthermore, both variables correlated with the lactulose-mannitol ratio, diamine oxidase, lipopolysaccharide and interleukin-8. CONCLUSION: Our data demonstrate the prognostic value of sCD163 in predicting long-term survival in patients with liver cirrhosis and identify soluble mannose receptor as a prognostic marker for occurrence of cirrhosis-associated complications. The correlation between gut barrier dysfunction and activation of macrophages points towards a link between them.
Authors: Anthony Rode; Amanda Nicoll; Holger Jon Møller; Lucy Lim; Peter W Angus; Ian Kronborg; Niranjan Arachchi; Alexandra Gorelik; Danny Liew; Konstantin Kazankov; Hendrik Vilstrup; Henning Grønbæk Journal: Gut Date: 2013-02-26 Impact factor: 23.059
Authors: G Dultz; L Gerber; H Farnik; A Berger; J Vermehren; T Pleli; S Zeuzem; A Piiper; B Kronenberger; O Waidmann Journal: J Viral Hepat Date: 2014-09-02 Impact factor: 3.728
Authors: Konstantin Kazankov; Francisco Barrera; Holger Jon Møller; Bo Martin Bibby; Hendrik Vilstrup; Jacob George; Henning Grønbaek Journal: Hepatology Date: 2014-05-06 Impact factor: 17.425
Authors: Maria Ruweka Fernando; Jose Luis Reyes; Jordan Iannuzzi; Gabriella Leung; Derek Mark McKay Journal: PLoS One Date: 2014-04-15 Impact factor: 3.240
Authors: Ali A Mokdad; Alan D Lopez; Saied Shahraz; Rafael Lozano; Ali H Mokdad; Jeff Stanaway; Christopher J L Murray; Mohsen Naghavi Journal: BMC Med Date: 2014-09-18 Impact factor: 8.775
Authors: A Horvath; B Leber; B Schmerboeck; M Tawdrous; G Zettel; A Hartl; T Madl; S Stryeck; D Fuchs; S Lemesch; P Douschan; E Krones; W Spindelboeck; F Durchschein; F Rainer; G Zollner; R E Stauber; P Fickert; P Stiegler; V Stadlbauer Journal: Aliment Pharmacol Ther Date: 2016-09-04 Impact factor: 8.171
Authors: Karen L Thomsen; Francis P Robertson; Peter Holland-Fischer; Brian R Davidson; Rajeshwar P Mookerjee; Holger J Møller; Rajiv Jalan; Henning Grønbæk Journal: J Clin Exp Hepatol Date: 2018-10-05